Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 38.41 Million USD | -25.99% |
| 2022 | 52.93 Million USD | 2.72% |
| 2021 | 51.53 Million USD | 59.21% |
| 2020 | 32.37 Million USD | 22.14% |
| 2019 | 26.5 Million USD | -23.85% |
| 2018 | 34.8 Million USD | -49.28% |
| 2017 | 68.61 Million USD | -35.29% |
| 2016 | 106.03 Million USD | 86.44% |
| 2015 | 56.87 Million USD | 13.86% |
| 2014 | 49.94 Million USD | 112.73% |
| 2013 | 23.48 Million USD | 43.02% |
| 2012 | 16.41 Million USD | -9.65% |
| 2011 | 18.17 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.63 Million USD | -31.74% |
| 2024 Q1 | 9.72 Million USD | 13.68% |
| 2023 Q2 | 9.12 Million USD | -8.69% |
| 2023 FY | 35.85 Million USD | -32.28% |
| 2023 Q4 | 8.55 Million USD | -3.17% |
| 2023 Q3 | 8.83 Million USD | -3.25% |
| 2023 Q1 | 9.99 Million USD | 9.64% |
| 2022 Q1 | 16.27 Million USD | 18.8% |
| 2022 FY | 52.93 Million USD | 2.72% |
| 2022 Q4 | 9.11 Million USD | -29.58% |
| 2022 Q3 | 12.94 Million USD | -11.29% |
| 2022 Q2 | 14.59 Million USD | -10.3% |
| 2021 FY | 51.53 Million USD | 59.21% |
| 2021 Q2 | 13.99 Million USD | 39.88% |
| 2021 Q4 | 13.69 Million USD | -1.04% |
| 2021 Q1 | 10 Million USD | -15.94% |
| 2021 Q3 | 13.84 Million USD | -1.09% |
| 2020 Q4 | 11.9 Million USD | 41.85% |
| 2020 Q1 | 5.82 Million USD | -10.43% |
| 2020 Q2 | 6.25 Million USD | 7.47% |
| 2020 FY | 32.37 Million USD | 22.14% |
| 2020 Q3 | 8.39 Million USD | 34.07% |
| 2019 Q4 | 6.5 Million USD | -25.75% |
| 2019 Q3 | 8.75 Million USD | 45.12% |
| 2019 Q1 | 5.21 Million USD | -23.55% |
| 2019 Q2 | 6.03 Million USD | 15.71% |
| 2019 FY | 26.5 Million USD | -23.85% |
| 2018 Q1 | 9.67 Million USD | -21.64% |
| 2018 FY | 34.8 Million USD | -49.28% |
| 2018 Q4 | 6.82 Million USD | -6.03% |
| 2018 Q3 | 7.25 Million USD | -34.34% |
| 2018 Q2 | 11.05 Million USD | 14.31% |
| 2017 Q2 | 19.88 Million USD | -5.2% |
| 2017 Q1 | 20.97 Million USD | -41.47% |
| 2017 FY | 68.61 Million USD | -35.29% |
| 2017 Q4 | 12.34 Million USD | -19.93% |
| 2017 Q3 | 15.41 Million USD | -22.49% |
| 2016 Q1 | 19.67 Million USD | 13.25% |
| 2016 Q2 | 20.9 Million USD | 6.25% |
| 2016 FY | 106.03 Million USD | 86.44% |
| 2016 Q4 | 35.83 Million USD | 20.95% |
| 2016 Q3 | 29.62 Million USD | 41.76% |
| 2015 Q3 | 12.43 Million USD | -7.12% |
| 2015 Q1 | 13.68 Million USD | 3.35% |
| 2015 Q2 | 13.38 Million USD | -2.23% |
| 2015 FY | 56.87 Million USD | 13.86% |
| 2015 Q4 | 17.36 Million USD | 39.74% |
| 2014 Q2 | 11.5 Million USD | 19.19% |
| 2014 Q1 | 9.65 Million USD | 14.97% |
| 2014 FY | 49.94 Million USD | 112.73% |
| 2014 Q4 | 13.24 Million USD | -14.78% |
| 2014 Q3 | 15.54 Million USD | 35.08% |
| 2013 Q2 | 4.36 Million USD | 51.78% |
| 2013 Q1 | 2.87 Million USD | -15.16% |
| 2013 Q4 | 8.39 Million USD | 7.09% |
| 2013 FY | 23.48 Million USD | 43.02% |
| 2013 Q3 | 7.84 Million USD | 79.59% |
| 2012 Q4 | 3.39 Million USD | -19.3% |
| 2012 Q3 | 4.2 Million USD | 0.0% |
| 2012 FY | 16.41 Million USD | -9.65% |
| 2011 FY | 18.17 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -5709.307% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -314.469% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -28.073% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 42.793% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -142.46% |
| Better Therapeutics, Inc. | 38.26 Million USD | -0.395% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 5.594% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -209.964% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -13.5% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -11.604% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 64.585% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -3769.123% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -17.871% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 18.185% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -3062.376% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -92.65% |
| Molecular Templates, Inc. | 63.09 Million USD | 39.115% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -175.726% |
| NexImmune, Inc. | 28.16 Million USD | -36.373% |
| Orgenesis Inc. | 45.75 Million USD | 16.05% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -49.776% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -52222.382% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -137.921% |
| Scopus BioPharma Inc. | 11.71 Million USD | -227.899% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 90.482% |
| Statera Biopharma, Inc. | 28.82 Million USD | -33.242% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -102.932% |
| Vaxxinity, Inc. | 56.05 Million USD | 31.468% |
| Vaccinex, Inc. | 23.45 Million USD | -63.773% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -3568.941% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 24.224% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -428.041% |